Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05850234 · ClinicalTrials.gov registry record · Phase 1

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
20
Study locations

NCT05850234: Recruiting Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by AstraZeneca.

NCT05850234 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 80 participants, below the 167-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05850234, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Primary Outcome

The incidence and severity of AEs.

Conditions Studied

Relapsed/Refractory Multiple Myeloma

Interventions

  • BIOLOGICAL GC012F (AZD0120)

Study Locations (20)

California

  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - San Francisco

Florida

  • Research Site - Jacksonville
  • Research Site - Miami
  • Research Site - Tampa

Colorado

  • Research Site - Aurora
  • Research Site - Denver

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

Michigan

  • Research Site - Ann Arbor
  • Research Site - Detroit

Minnesota

  • Research Site - Minneapolis
  • Research Site - Rochester

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Phoenix

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-07-20
Est. Completion 2028-11-15
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT05850234 shows while recruiting

NCT05850234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 167-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which GC012F (AZD0120) is the first listed.

NCT05850234 names 20 study sites across 12 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT05850234 about?

NCT05850234 is a clinical study titled "A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma". This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

What is the current status of trial NCT05850234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-07-20. Estimated completion is 2028-11-15.

What conditions does trial NCT05850234 study?

This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.

What interventions are being tested in trial NCT05850234?

The interventions under investigation include: GC012F (AZD0120) (BIOLOGICAL).

Who is sponsoring clinical trial NCT05850234?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05850234 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed/Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05850234's enrollment target sits among peer trials

80 10th of 14 higher than 5 of 14 other Relapsed/Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05850234

Source: ClinicalTrials.gov NCT05850234, the US trial registry maintained by the National Library of Medicine. NCT05850234 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.